After much anticipation, Sandoz has finally received US Food and Drug Administration approval for its pegfilgrastim biosimilar, Ziextenzo (pegfilgrastim-bmez).
With the approval of Ziextenzo, Sandoz noted that it would become the only company to “offer US physicians long- and...






